India's Richest People 2026 edition · 1 director · Source: Hurun India
- #763 Shivanand Dattatraya Sawant & family ₹4,100 Cr
Revenue · FY 2025
₹1,060.17 Cr
▲ 22% YoY
Net profit · FY 2025
₹189.99 Cr
Net margin 17.9%
EBITDA · FY 2025
₹293.82 Cr
EBITDA margin 27.7%
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹18.5 Cr
Issued & subscribed
Open charges
₹122 Cr
Satisfied ₹239.9 Cr
Company age
46 yrs
Est. 1980
Employees · EPFO
3,274
Provident fund records
About Centaur Pharmaceuticals Private Limited
Data last updated:
Centaur Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 15 October 1980 and has been in existence for over 46 years.
Its director Shivanand Dattatraya Sawant and family are #763 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH1980PTC023291. Its GSTIN is 27AAACC0444K1ZV (Maharashtra). The company holds 19 GST registrations, of which 17 are active.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹18.5 Cr. It was formerly known as Centaur Pharmaceuticals Limited. It is led by directors including Shivanand Dattatray Sawant (Managing Director) and Shreekant Dattathray Sawant (Managing Director).
Its last annual general meeting (AGM) was held on 18 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Centaur House Shanti Nagar Vakola Santacruz (E), Mumbai, Maharashtra, India – 400055.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,060.17 Cr, a growth of 22% compared to the previous year. For the same year it recorded a net profit of ₹189.99 Cr (net margin 17.9%) and EBITDA of ₹293.82 Cr (EBITDA margin 27.7%). Revenue has grown at a compounded annual rate (CAGR) of 4% over three years and 7% over five years.
The company has about 3,274 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Centaur Pharmaceuticals. As per MCA filings, the company has open charges of ₹122 Cr and satisfied charges of ₹239.9 Cr on record. Court records list 196 cases involving the company, including 161 filed by the company and 35 filed against it; 32 cases are pending. The company has 20 deals on record (16 secondary share transfers, 4 funding rounds), with disclosed funding of ₹38.78 Cr; the latest was in February 2025. Its 9 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Metrochem Api Private Limited with revenue of ₹1,107 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website centaurpharma.com.
Company details
CIN U24230MH1980PTC023291
Registration Number 023291
Incorporation Date 15 October 1980
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 18 September 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Shivanand Dattatray Sawant Managing Director Shreekant Dattathray Sawant Managing Director Rakhi Shridhar Kadam Whole-Time Director Recognitions & Rankings of Centaur Pharmaceuticals
Contact details
Centaur Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra. Its website is centaurpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressCentaur House Shanti Nagar Vakola Santacruz (E), Mumbai, Maharashtra, India – 400055
- IndustryPharma, API Manufacturers
To see the full contact details of Centaur Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Centaur Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Centaur Pharmaceuticals operates one associated brand: Centaur Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Branded formulations and APIs are developed and manufactured. | centaurpharma.com |
Business activity
The main business activities of Centaur Pharmaceuticals are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and scientific research and development. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Centaur Pharmaceuticals Private Limited, buy the company report.
Financials of Centaur Pharmaceuticals Private Limited
FY 2026 filings availableCentaur Pharmaceuticals Private Limited reported revenue of ₹1,060.17 Cr (up 22% YoY) for FY 2025.
Revenue · FY 2025
₹1,060.17 Cr ▲ 22%
Net profit · FY 2025
₹189.99 Cr margin 17.9%
EBITDA · FY 2025
₹293.82 Cr margin 27.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 22%
3 years · compounded
▲ 4%
5 years · compounded
▲ 7%
EBITDA CAGR growth
1 year
▲ 70%
3 years · compounded
▲ 1%
5 years · compounded
▲ 6%
Revenue has grown at a compounded annual rate (CAGR) of 7% over five years, including 22% growth in the latest year. EBITDA rose 70% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹293.82 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹189.99 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 27.7% | ||||
| Net Profit Margin | 17.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Centaur Pharmaceuticals Private Limited, buy the company report.
Board of directors of Centaur Pharmaceuticals Private Limited
Centaur Pharmaceuticals has 7 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sharadchandra Damodar Abhyankar | Director | 11 Aug 2016 | 10 Years 2 Months | Current |
| Albert Tauro | Director | 11 Aug 2016 | 10 Years 2 Months | Current |
| Rakhi Shridhar Kadam | Whole-Time Director | 14 Sep 2015 | 11 Years 1 Months | Current |
| Smita Abhayakumar Phal | Whole-Time Director | 22 Jun 2011 | 15 Years 4 Months | Current |
| Shivanand Dattatray Sawant Also directs: Minesfield Advisory Services LLP | Managing Director | 15 Oct 1980 | 46 Years 0 Months | Current |
| Shreekant Dattathray Sawant Also directs: Minesfield Advisory Services LLP | Managing Director | 01 Aug 2008 | 18 Years 2 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Centaur Pharmaceuticals Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Metrochem Api Private Limited | ₹1,107 Cr (FY 2025) | 1.0% | Hyderabad, Telangana, India | |||
| Troikaa Pharmaceuticals Limited | ₹1,088.44 Cr (FY 2025) | 12.0% | Ahmedabad, Gujarat, India | |||
| Blue Jet Healthcare Limited | ₹1,076.24 Cr (FY 2025) | 45.0% | Navi Mumbai, Maharashtra, India | |||
| Tenshi Pharmaceuticals Private Limited | ₹1,071.06 Cr (FY 2024) | 98.0% | Bangalore, Karnataka, India | |||
| Centaur Pharmaceuticals Private Limitedthis company | ₹1,060.17 Cr (FY 2025) | ₹189.99 Cr | 17.9% | 22.0% | 3,274 | Mumbai, Maharashtra, India |
| Dalas Biotech Limited | ₹1,050.04 Cr (FY 2024) | 43.0% | Bhiwadi, Rajasthan, India | |||
| Acutaas Chemicals Limited | ₹1,023.8 Cr (FY 2025) | 41.0% | Surat, Gujarat, India | |||
| Watson Pharma Private Limited | ₹1,019.98 Cr (FY 2025) | -7.0% | Mumbai, Maharashtra, India | |||
| Otsuka Chemical (India) Private Limited | ₹1,013.6 Cr (FY 2025) | -5.0% | New Delhi, Delhi, India | |||
| Franco-Indian Pharmaceuticals Private Limited | ₹988.53 Cr (FY 2024) | 0.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Centaur Pharmaceuticals Private Limited, buy the company report.
Auditor
Centaur Pharmaceuticals Private Limited is audited by Deloitte Haskins & Sells LLP Name of auditor signing report BHATT for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells LLP Name of auditor signing report BHATT | FY 2023 | 117366W / W-100018 |
Shareholding
The shareholding of Centaur Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Centaur Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹122 Cr
Satisfied charges
₹239.9 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 03 May 2011 | 10291402 | State Bank of India | ₹61 Cr | Open | |
| 03 Aug 2006 | 10015268 | State Bank of India | ₹61 Cr | Open | |
| 26 May 2015 | 10585265 | Tata Capital Financial Services Limited | ₹1.7 Cr | Satisfied | |
| 27 Jan 2015 | 10548643 | Tata Capital Financial Services Limited | ₹3 Cr | Satisfied | |
| 19 May 2014 | 10501908 | Tata Capital Financial Services Limited | ₹12.5 Cr | Satisfied |
To see the full charge records of Centaur Pharmaceuticals Private Limited, buy the company report.
Total charge records: 35 View all charges
Deals & funding
Centaur Pharmaceuticals Private Limited has 20 deals on record (16 secondary share transfers, 4 funding rounds), with disclosed funding of ₹38.78 Cr; the latest was in February 2025.
Total deals
20
Secondary share transfers
16
Funding rounds
4
Disclosed funding
₹38.78 Cr
Deals on record (5 of 20)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2018 | Secondary share transfer | Undisclosed | Buyer: Minesfield Advisory Services LLP , an individual Seller: Chiron Realty Private Limited , an individual |
| Aug 2016 | Secondary share transfer | Undisclosed | Seller: Minesfield Advisory Services LLP , an individual |
| Mar 2014 | Secondary share transfer | Undisclosed | Buyer: Chiron Realty Private Limited , 2 individuals Seller: SIDBI Ventures, 2 individuals |
| Mar 2007 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Centaur Laboratories Private Limited |
| May 2006 | Funding round | ₹5.74 Cr | Investors: Centaur Laboratories Private Limited , 3 individuals |
To see the full deal history of Centaur Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Centaur Pharmaceuticals Private Limited has 196 court cases on record: 161 filed by Centaur Pharmaceuticals, 35 filed against it. 32 cases are pending and 164 are disposed.
Total cases
196
Filed by the company
161
Filed against the company
35
Pending
32
Disposed
164
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 137 | 22 | 26 |
| District courts | 55 | 12 | 6 |
| Supreme Court | 4 | 1 | 0 |
Cases on record (5 of 196)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (CRR) | Filed by the company against Sightcare Pharma LLP and Anr | Pending |
| High Court | Court case (COMIP) | Filed by the company against Surien Pharmaceuticals Private Limited and 1 other | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed by the company against Torque Pharmaceuticals Pvt. Ltd. | Pending |
| High Court, MAHARASHTRA | Court case (COMMP) | Filed by the company against Aquatic Formulations (India) Ltd. and Anr. and 1 other | Pending |
| High Court, MAHARASHTRA | Court case (COMIP) | Filed by the company against MDC Pharmaceuticals Limited and 1 other | Pending |
To see the full case history of Centaur Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Centaur Pharmaceuticals Private Limited was last rated by Crisil on 07 Apr 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 07 Apr 2020 |
To see the full credit ratings and regulatory alerts of Centaur Pharmaceuticals Private Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Centaur Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Centaur Pharmaceuticals Private Limited has a workforce of 3,274 employees on its EPFO records as of Oct 11, 2024, across 4 active EPFO establishments.
Employee count
3,274
Active EPFO establishments
4
Employee growth
1.71%
GST
Centaur Pharmaceuticals has 19 GST registrations: 17 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
19
Active
17
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACC0444K1ZV | Maharashtra | Active | 01 Jul 2017 |
| 03AAACC0444K1Z5 | Punjab | Active | 01 Jul 2017 |
| 05AAACC0444K1Z1 | Uttarakhand | Active | 01 Jul 2017 |
| 07AAACC0444K1ZX | Delhi | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Centaur Pharmaceuticals Private Limited, buy the company report.
Recent activity
Centaur Pharmaceuticals Private Limited has 17 board changes on record since 1980: 7 appointments and 10 cessations. The latest: Supriya Samar Desai ceased to be Additional Director on 25 Aug 2022.
AGM
Centaur Pharmaceuticals Private Limited last Annual general meeting of members was held on 18 Sep 2026 as per latest MCA records.
Filing
Centaur Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with State Bank Of India of Rs. 61.00 Cr registered on 03 May 2011 with Charge ID 10291402 was modified on 12 Mar 2026.
Charges
A charge with State Bank Of India of Rs. 61.00 Cr registered on 03 Aug 2006 with Charge ID 10015268 was modified on 12 Mar 2026.
Ceased
Supriya Samar Desai ceased to be Additional Director.
Appointed
Supriya Samar Desai was appointed as Whole-Time Director.
Ceased
Anil Mahadev Naik ceased to be Whole-Time Director.
Appointed
Albert Tauro was appointed as Director.
Appointed
Sharadchandra Damodar Abhyankar was appointed as Director.
Charges
A charge registered on 26 May 2015 via Charge ID 10585265 with Tata Capital Financial Services Limited was fully satisfied on 29 Mar 2016.
Charges
A charge registered on 27 Jan 2015 via Charge ID 10548643 with Tata Capital Financial Services Limited was fully satisfied on 29 Mar 2016.
Charges
A charge registered on 10 Dec 2013 via Charge ID 10468294 with Tjsb Sahakari Bank Limited was fully satisfied on 04 Dec 2015.
92 earlier events are in the company report.
News
Frequently asked questions
Centaur Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 15 October 1980 (46+ years old) and is registered under CIN U24230MH1980PTC023291.
Centaur Pharmaceuticals has 7 current directors:
- Shivanand Dattatray Sawant - Managing Director
- Shreekant Dattathray Sawant - Managing Director
- Rakhi Shridhar Kadam - Whole-Time Director
- Smita Abhayakumar Phal - Whole-Time Director
- Supriya Samar Desai - Whole-Time Director
- Sharadchandra Damodar Abhyankar - Director
- Albert Tauro - Director
The latest financial statements of Centaur Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 18 September 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Centaur Pharmaceuticals is 27AAACC0444K1ZV, registered in Maharashtra. The company has 19 GST registrations in all, of which 17 are active and 2 are cancelled or inactive. Other active GSTINs include 03AAACC0444K1Z5 (Punjab), 05AAACC0444K1Z1 (Uttarakhand), 07AAACC0444K1ZX (Delhi).
The CIN (Corporate Identification Number) of Centaur Pharmaceuticals is U24230MH1980PTC023291. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Centaur Pharmaceuticals has 196 court cases on record: 161 filed by the company and 35 filed against it. 32 are pending. Most are in the high courts.
Centaur Pharmaceuticals was incorporated on 15 October 1980, making it 46+ years old. It is registered with the Registrar of Companies, Mumbai.
Centaur Pharmaceuticals has 20 deals on record (16 secondary share transfers, 4 funding rounds), with disclosed funding of ₹38.78 Cr; the latest was in February 2025.
The peers of Centaur Pharmaceuticals by revenue are Metrochem Api Private Limited, Troikaa Pharmaceuticals Limited, Blue Jet Healthcare Limited, Tenshi Pharmaceuticals Private Limited, Dalas Biotech Limited and 4 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Supriya Samar Desai ceased to be Additional Director on 25 Aug 2022. Supriya Samar Desai was appointed as Whole-Time Director on 21 Dec 2021. Anil Mahadev Naik ceased to be Whole-Time Director on 11 Jun 2019. Centaur Pharmaceuticals has 17 board changes on record in total.
Centaur Pharmaceuticals can be reached through the website centaurpharma.com. Its registered office is in Mumbai, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages